1. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx. www.pfizer.com/news/press-release/press-release-detail/akcea_and_pfizer_inc_announce_licensing_agreement_for_investigative_antisense_therapy_akcea_angptl3_lrx
2. Ionis Pharmaceuticals: About. www.ionispharma.com/about/
3. Ionis Pharmaceuticals: optimising antisense. www.ionispharma.com/ionis-innovation/optimizing-antisense/
4. Akcea Therapeutics: Pipeline. https://akceatx.com/our-programs/pipeline/
5. UCB agrees to acquire Ra Pharmaceuticals: Joining forces to improve treatment options for people living with myasthenia gravis and other rare diseases. www.ucb.com/stories-media/Press-Releases/article/UCB-agrees-to-acquire-Ra-Pharmaceuticals-Joining-forces-to-improve-treatment-options-for-people-living-with-myasthenia-gravis-and-other-rare-diseases